The LRRK2 R1441C mutation is more frequent than G2019S in Parkinson's disease patients from Southern Italy

Movement Disorders

Volumn 26, Issue 9, 2011, Pages 1732-1736

  Criscuolo, Chiara ^a,b   De Rosa, Anna ^b   Guacci, Anna ^b   Simons, Erik J ^a   Breedveld, Guido J ^a   Peluso, Silvio ^b   Volpe, Giampiero ^c   Filla, Alessandro ^b   Oostra, Ben A ^a   Bonifati, Vincenzo ^a   De Michele, Giuseppe ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c S Giovanni di Dio e Ruggi d'Aragona Hospital   (Italy)

Author keywords

G2019S; Leucine rich repeat kinase 2; PARK8; R1441C

Indexed keywords

GENOMIC DNA; LEUCINE RICH REPEAT KINASE 2; AMINO ACID; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; FAMILY HISTORY; FEMALE; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; ONSET AGE; PARKINSON DISEASE; PATIENT COUNSELING; PEDIGREE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE; DISABILITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AMINO ACIDS; DISABILITY EVALUATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ITALY; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES;

EID: 79961207766     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23735     Document Type: Article

References (20)

1. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med. 2009; 11: e22.
2. Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. 2005; 365: 412-415.
3. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet. 2005; 365: 410-412.
4. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005; 365: 415-416.
5. Paiśn-Ruiz C. LRRK2 gene variation and its contribution to Parkinson disease. Hum Mutat. 2009; 30: 1153-1160.
6. Correia Guedes L, Ferreira JJ, Rosa MM, et al. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord. 2010; 16: 237-242.
7. De Rosa A, Criscuolo C, Mancini P, et al. Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy. Parkinsonism Relat Disord. 2009; 15: 242-244.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55: 181-184.
9. Goldwurm S, Di Fonzo A, Simons EJ, et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet. 2005; 42: e65.
10. Haugarvoll K, Rademakers R, Kachergus JM, et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology. 2008; 70: 1456-1460.
11. Di Fonzo A, Tassorelli C, De Mari M, et al. Italian Parkinson's Genetics Network. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet. 2006; 14: 322-331.
12. De Michele G, Filla A, Volpe G, et al. Environmental and genetic risk factors in Parkinson's disease: a case control study in southern Italy. Mov Disord. 1996; 11: 17-23.
13. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004; 44: 601-607.
14. Gosal D, Lynch T, Ross OA, Haugarvoll K, Farrer MJ, Gibson JM. Global distribution and reduced penetrance: Lrrk2 R1441C in an Irish Parkinson's disease kindred. Mov Disord. 2007; 22: 291-292.
15. Nuytemans K, Rademakers R, Theuns J, et al. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur J Hum Genet. 2008; 16: 471-479.
16. Tan EK, Skipper L, Chua E, et al. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease. Mov Disord. 2006; 21: 997-1001.
17. Shojaee S, Sina F, Farboodi N, et al. A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson's disease patients. Mov Disord. 2009; 24: 1023-1027.
18. Healy DG, Falchi M, O'sullivan SS, et al. International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008; 7: 583-590.
19. Floris G, Cannas A, Solla P, et al. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. Parkinsonism Relat Disord. 2009; 15: 277-280.
20. Wszolek ZK, Pfeiffer B, Fulgham JR, et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology. 1995; 45: 502-505.